Compare ARAY & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARAY | SCYX |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.3M | 44.0M |
| IPO Year | 2006 | 2014 |
| Metric | ARAY | SCYX |
|---|---|---|
| Price | $0.28 | $4.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $3.50 | $3.00 |
| AVG Volume (30 Days) | ★ 1.8M | 94.7K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.58 | $608.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.57 |
| 52 Week High | $2.10 | $5.62 |
| Indicator | ARAY | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 63.96 |
| Support Level | $0.28 | $0.67 |
| Resistance Level | $0.36 | $5.62 |
| Average True Range (ATR) | 0.03 | 0.31 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 47.37 | 77.27 |
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.